{"paper_id":"45b2dd4b-c83f-462a-a47c-dac35bf83816","body_text":"Abstract\nThe coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin dependent kinases (CDKs) together with CDC7 kinase, are essential to origin activation by converting the pre-replicative complex into a fully active helicase.\nTo identify genes that tune DNA replication, we have performed a chemo-genetic genome-wide CRISPR-KO screen with cells challenged with the CDC7 inhibitor XL413. By developing a methodology based on genetic coessentiality to functionally cluster the hits, we uncover the transcriptional CDK8/CCNC kinase in a cluster with replication initiation factors. We find that CDK8 depletion further reduces the rate of DNA synthesis imposed by CDC7 inhibitors. DNA fibre experiments provide compelling evidence that CDK8 and CDC7 cooperate in origin activation.\nSuppression of DNA synthesis by CDK8 inhibition requires the binding of CDK8/CCNC to the MDM2 Binding Protein (MTBP) and we show that CDC7 and CDK8 individually contribute to the phosphorylation of MCM4 subunit of the replicative helicase.\nThus, this work identifies CDK8 as the third protein kinase directly involved in origin activation in human cells.\nCompeting Interest Statement\nM. D. Rainey and C. Santocanale are inventor on EP4275686A1 patent assigned to the University of Galway with title Combination therapy for cancer comprising a cdc7 inhibitor and a cdk8 inhibitor or a ccnc inhibitor.\nFootnotes\nMinor changes/edits in the text for improved clarity; ORCID for authors updated.","source_license":"CC-BY-4.0","license_restricted":false}